DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call...
/Female%20scientist%20using%20microscope%20making%20lab%20analysis%20by%20aFotostock%20via%20Adobe%20Stock.jpeg)
DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a double-digit percentage.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Patient Monitoring Stocks Q1 Results: Benchmarking DexCom (NASDAQ:DXCM)
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down
At Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States. The...
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky